Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression

被引:19
作者
Sakakibara, Ayako [1 ]
Inagaki, Yuichiro [2 ]
Imaoka, Eiki [3 ]
Ishikawa, Eri [1 ]
Shimada, Satoko [1 ]
Shimada, Kazuyuki [4 ]
Suzuki, Yuka [1 ]
Nakamura, Shigeo [1 ]
Satou, Akira [5 ]
Kohno, Kei [1 ]
机构
[1] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan
[2] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Japan
[3] Anjo Kosei Hosp, Dept Neurosurg, Anjo, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi, Japan
[5] Aichi Med Univ Hosp, Dept Surg Pathol, Aichi, Japan
关键词
intravascular large B-cell lymphoma; neoplastic PD-L1 expression;
D O I
10.3960/jslrt.17037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intravascular large B-cell lymphoma (IVLBCL) is a rare and clinically distinctive entity characterized by the almost exclusive growth of large cells within the lumen of blood vessels in particular capillaries. Reports of this peculiar disease, do not commonly address the PD-L1 expression on IVLBCL tumor cells. Here, we describe a 51-year-old Japanese woman who presented with rapidly progressive cognitive decline and higher brain dysfunction. CT scan and MRI revealed multiple ischemic foci in the cerebral hemispheres, ground-glass opacity in the lungs, and splenomegaly. Random skin biopsy for IVLBCL diagnosis yielded negative results. The patient experienced a rapidly deteriorating clinical course with no treatment, and died from the disease after 3 months of hospitalization. Post-mortem examination revealed systemic intravascular plugging of lymphoma cells, without mass lesions in the central nervous system or in visceral organs such as the lungs, liver, pituitary gland, ovaries, and uterus. The tumor cells were positive for CD10, CD20, BCL2, BCL6, and MUM1, but not other lineage-specific markers. Notably, the tumor cells showed strong PD-L1 expression. Our case was diagnosed as IVLBCL with neoplastic PD-L1 expression. These findings suggest that PD-L1 is associated with immune evasion of IVLBCL and may play a role in the pathogenesis and peculiar biological behavior of this unique disease. Additionally, PD-L1 may represent a possible therapeutic target for immune check-point inhibitors.
引用
收藏
页码:32 / 35
页数:4
相关论文
共 17 条
[1]   PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies [J].
Chen, Benjamin J. ;
Chapuy, Bjoern ;
Jing Ouyang ;
Sun, Heather H. ;
Roemer, Margaretha G. M. ;
Xu, Mina L. ;
Yu, Hongbo ;
Fletcher, Christopher D. M. ;
Freeman, Gordon J. ;
Shipp, Margaret A. ;
Rodig, Scott J. .
CLINICAL CANCER RESEARCH, 2013, 19 (13) :3462-3473
[2]   PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival [J].
Four, Marion ;
Cacheux, Valere ;
Tempier, Ariane ;
Platero, Dolores ;
Fabbro, Michel ;
Marin, Gregory ;
Leventoux, Nicolas ;
Rigau, Valerie ;
Costes-Martineau, Valerie ;
Szablewski, Vanessa .
HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) :487-496
[3]   An autopsy case of lymphomatosis cerebri showing pathological changes of intravascular large B-cell lymphoma in visceral organs [J].
Hishikawa, Nozomi ;
Niwa, Hisayoshi ;
Hara, Takashi ;
Hara, Kazuhiro ;
Ito, Makoto ;
Shimada, Satoko ;
Yoshida, Mari ;
Hashizume, Yoshio ;
Murakami, Nobuyuki .
NEUROPATHOLOGY, 2011, 31 (06) :612-619
[4]   Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies [J].
Ilcus, Cristina ;
Bagacean, Cristina ;
Tempescul, Adrian ;
Popescu, Cristian ;
Parvu, Andrada ;
Cenariu, Mihai ;
Bocsan, Corina ;
Zdrenghea, Mihnea .
ONCOTARGETS AND THERAPY, 2017, 10 :2349-2363
[5]   Comparative clinicopathological study of primary CNS diffuse large B-cell lymphoma and intravascular large B-cell lymphoma [J].
Imai, Hiroshi ;
Shimada, Kazuyuki ;
Shimada, Satoko ;
Abe, Masato ;
Okamoto, Masataka ;
Kitamura, Kunio ;
Kinoshita, Tomohiro ;
Shiraishi, Taizo ;
Nakamura, Sigeo .
PATHOLOGY INTERNATIONAL, 2009, 59 (07) :431-437
[6]   PD-1 and its ligands in tolerance and immunity [J].
Keir, Mary E. ;
Butte, Manish J. ;
Freeman, Gordon J. ;
Sharpel, Arlene H. .
ANNUAL REVIEW OF IMMUNOLOGY, 2008, 26 :677-704
[7]   Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma [J].
Kiyasu, Junichi ;
Miyoshi, Hiroaki ;
Hirata, Akie ;
Arakawa, Fumiko ;
Ichikawa, Ayako ;
Niino, Daisuke ;
Sugita, Yasuo ;
Yufu, Yuji ;
Choi, Ilseung ;
Abe, Yasunobu ;
Uike, Naokuni ;
Nagafuji, Koji ;
Okamura, Takashi ;
Akashi, Koichi ;
Takayanagi, Ryoichi ;
Shiratsuchi, Motoaki ;
Ohshima, Koichi .
BLOOD, 2015, 126 (19) :2193-2201
[8]   Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas [J].
Kwon, Dohee ;
Kim, Sehui ;
Kim, Pil-Jong ;
Go, Heounjeong ;
Nam, Soo Jeong ;
Paik, Jin Ho ;
Kim, Young A. ;
Kim, Tae Min ;
Heo, Dae Seog ;
Kim, Chul Woo ;
Jeon, Yoon Kyung .
HISTOPATHOLOGY, 2016, 68 (07) :1079-1089
[9]   PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase [J].
Kwong, Yok-Lam ;
Chan, Thomas S. Y. ;
Tan, Daryl ;
Kim, Seok Jin ;
Poon, Li-Mei ;
Mow, Benjamin ;
Khong, Pek-Lan ;
Loong, Florence ;
Au-Yeung, Rex ;
Iqbal, Jabed ;
Phipps, Colin ;
Tse, Eric .
BLOOD, 2017, 129 (17) :2437-2442
[10]   High Frequency of Neurolymphomatosis as a Relapse Disease of Intravascular Large B-Cell Lymphoma [J].
Matsue, Kosei ;
Hayama, Brian Y. ;
Iwama, Kan-Ichi ;
Koyama, Takafumi ;
Fujiwara, Hideaki ;
Yamakura, Masayuki ;
Takeuchi, Masami ;
O'uchi, Toshihiro .
CANCER, 2011, 117 (19) :4512-4521